PUBLICATIONS & ABSTRACTS: CLINICAL EVIDENCE
100s of extensive peer reviewed publications and studies utilizing MammaPrint + BluePrint have observed benefits from treatment in the following areas of clinical utility:
Scientific evidence for clinical utility.
By continually expanding and strengthening our database of proven research including 20+ years of clinical validation and 200+ research collaborations, we have gained widespread trust in the precision, accuracy and quality of our MammaPrint® and BluePrint® test suite.
Evidence
ASCO June 5 2019: Race and response to neoadjuvant chemotherapy
AUTHORS: Raquel Nunes, Femke de Snoo, Lisette Stork-Sloots, Tina Treece, Christa Dreezen, William Audeh DESCRIPTION: Race and response to neoadjuvant chemotherapy according to MammaPrint risk African-American (AA) women with breast cancer have a less favorable prognosis, likely due to differences in tumor biology. The Neoadjuvant BReast Cancer Symphony Trial (NBRST, Read More
2019 ASCO FLEX Poster
AUTHORS: Gordan Srkalovic, Adam Brufsky, Jennifer Crozier, Mehran Habibi, Pat Whitworth, Charles Cox, Ian Grady, Nina D’Abreo, Sarah Untch, Erin Yoder, William Audeh, FLEX Investigators Group DESCRIPTION: Clinical Trial in Progress: The FLEX Big Data Platform Explores New Gene Expression Profiles and Investigator-Initiated Protocols in Early Stage Breast Cancer Genomic Read More
Strong Impact of MammaPrint and BluePrint on Treatment Decisions in Luminal Early Breast Cancer: Results of the WSG-PRIMe Study
PUBLICATION: Breast Cancer Res Treat. (2019) 175: 389. https://doi.org/10.1007/s10549-018-05075-x. AUTHORS: R. Wuerstlein, R. Kates, O. Gluz, E.M. Grischke, C. Schem, M. Thill, S. Hasmueller, A. Köhler, B. Otremba, F. Griesinger, C. Schindlbeck, A. Trojan, F. Otto, M. Knauer, R. Pusch, N. Harbeck, WSG-PRIMe investigators in Germany, Austria, Switzerland SUMMARY: MammaPrint Read More
NBRST: ER-positive basal-type breast cancers, respond like TNBC
NPJ Breast Cancer, April 2019 Author: Groenendijk et al.
Read MoreEstrogen Receptor Variants in ER-Positive Basal-Type Breast Cancers Responding to Therapy Like ER-Negative Breast Cancers
PUBLICATION: npj Breast Cancer; volume 5, Article number: 15 (2019). AUTHORS: Floris H. Groenendijk, Tina Treece, Erin Yoder, Paul Baron, Peter Beitsch, William Audeh, Winand N. M. Dinjens, Rene Bernards & Pat Whitworth ABSTRACT: Immunohistochemically ER-positive HER2-negative (ER+HER2−) breast cancers are classified clinically as Luminal-type. We showed previously that molecular Read More
Reclassification of Early Stage Breast Cancer Into Treatment Groups by Combining the Use of Immunohistochemistry and Microarray Analysis
PUBLICATION: Vol 115 No 3/4 (2019): South African Journal of Science. AUTHORS: Kathleen A. Grant; Ettienne J. Myburgh; Elizabeth Murray; Fredrieka M. Pienaar; Martin Kidd; Colleen A. Wright; Maritha J. Kotze SUMMARY: Neither single-gene genomic mRNA nor IHC reporting of ER and PR status can replace the combined use of Read More
2018 SABCS FLEX Trials in Progress Poster
AUTHORS: Adam M. Brufsky, Jennifer A. Crozier, Ian Grady, Thomas Lomis, Pat Whitworth, Esther Rehmus, Gordon Srkalovic, Laura Lee, Peter Blumencranz, Paul Baron, Blanche Mavromatis, Sarah Untch, Lisa Blumencranz, Tina Treece, Erin Yoder, William Audeh. DESCRIPTION: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Read More